What is AI in healthcare?

Artificial intelligence in healthcare is the application of machine learning to medical information through the analysis of complex algorithms and software to enable data-driven solutions.

How does AAIH differentiate artificial intelligence and machine learning?

Artificial Intelligence is the broader concept of machines being able to carry out tasks in a way that we would consider “smart”. Machine Learning is a subset of AI based around the concept of iterative learning in which a system ‘learns’ from data input and modifies activity without human intervention. Please note that in our definition of integration of both Machine Learning and AI into healthcare today, AAIH includes iterative, feedback-based learning between machine and man.

How can AI help to address rising healthcare costs?

Artificial Intelligence can be deployed at every level of the healthcare system to disrupt all aspects of the healthcare management chain and improve inefficiencies, including in discovery, development, and delivery. Specific areas include:

Biomedical Discovery: Through the use of AI platforms, the industry can reduce failure rates in biomedical discovery by increasing the capacity to test an increased number and quality of druggable targets. This will improve the efficacy and availability of compounds available for a widely expanded range of indications.

Point of Care Delivery: Using AI platforms for clinical data management permits early and accurate diagnosis of a range of medical conditions through improved data aggregation, analysis, and pattern recognition. As a result, complicated data sets can be rapidly interrogated to drive early and effective treatment interventions.

What is the history of AAIH?

AAIH was launched in 2019 to better serve the growing need for guidance specifically for AI in healthcare. Artificial Intelligence has long been a concept carrying tremendous promise, with seemingly limitless potential to increase industry efficiency and improve lives on a global scale. As these discoveries and technologies move from the lab to the clinic, it’s important for governments, industry organizations, research institutions, biotech startups, large healthcare corporations and medical ethicists alike to work together to answer AI in healthcare’s challenges and promises.

Where does AAIH operate?

AAIH currently has a presence in Washington D.C., the European Union, and other primary regulatory jurisdictions as the primary voice for the AI in healthcare industry. As we move into the future, the organization will be successful in integrating AI platforms into the healthcare regulatory frameworks of multiple jurisdictions to stimulate innovation in drug discovery and to improve the overall quality of care.

What is the mission of AAIH?

AAIH is the global advocacy organization for the advancement and use of artificial intelligence in healthcare to improve patients’ lives and create more efficient, sustainable, and accessible healthcare systems. Through investment, invention, and innovation in AI, the AAIH and its member companies and organizations are creating novel interventions and product solutions that reduce failure rates and costs while improving quality across the entire healthcare spectrum.

What does AAIH identify as key steps to be taken by the industry and public policy groups to achieve the full potential of AI?

• Distinguish between hype and reality, set achievable expectations.

• Engage in educational outreach to unify industry voice, define AI in public arenas.

• Advocate for informed policy and appropriate regulatory standards.

• Unify the industry around key priorities, identify bottlenecks, and develop strategic industry-wide approaches for resolution

Who are the AAIH’s founding companies and organizations?

Founding members include Amazon WS, Bayer, Beyond Limits, BlackThorn Therapeutics, The Buck Institute for Research on Aging, Cyclica, Envisagenics, GE Healthcare, Genialis Inc, GSK, Insilico Medicine, Janssen, Minds.ai, Netrias, NuMedii, Numerate, Nuritas, OWKIN, Progenics Pharmaceuticals, Recursion, SimplicityBio and the University of Pittsburgh. We continue to seek members to diversify our foundational platforms and applications across the healthcare value chain.

What are the key healthcare industry categories represented within AAIH?

The AAIH vision is for precision healthcare-- spanning the entire healthcare continuum of biomedical discovery, clinical research and development, and clinical applications-- to foster the delivery of better medicine to patients and populations.

Biomedical Discovery: AI-enabled identification of new disease mechanisms, pathways, targets, drugs, diagnostics, and devices by various approaches including imaging and in-silico.

Clinical Research: AI-enabled acceleration and facilitation of Phase I-IV clinical trials including patient stratification, enrollment, retention, adherence, and monitoring as well as project management approaches.

Medical Diagnostics and Devices: AI approaches that enable image, drug/device, or treatment enhancement; may include diagnostics, wearables and implantable.

Precision Medicine: AI-based approaches that enhance patient or population health solutions and care; including diagnostics, genomics, imaging, pathology, patient data, precision and risk analytics. 

We encourage and anticipate the participation of numerous large pharmaceutical, biotech, diagnostics, and medical devices firms investing in or utilizing AI in their operations as well as the full gamut of tech firms participating in healthcare.

Who should join AAIH?

Any company or organization developing, investing, or applying AI platforms and products for healthcare and willing to sign a member code of conduct committing to specific industry expectations. At this time there are no individual memberships.

Who are the AAIH’s founding companies and organizations?

Founding members include Amazon WS, Bayer, Beyond Limits, BlackThorn Therapeutics, The Buck Institute for Research on Aging, Cyclica, Envisagenics, GE Healthcare, Genialis Inc, GSK, Insilico Medicine, Janssen, Minds.ai, Netrias, NuMedii, Numerate, Nuritas, OWKIN, Progenics Pharmaceuticals, Recursion, SimplicityBio and the University of Pittsburgh. We continue to seek members to diversify our foundational platforms and applications across the healthcare value chain.

Who should join AAIH?

Any company or organization developing, investing, or applying AI platforms and products for healthcare and willing to sign a member code of conduct committing to specific industry expectations. At this time there are no individual memberships. The key healthcare industry categories represented include:

Biomedical Discovery: AI enabled identification of new disease mechanisms, pathways, targets, drugs, diagnostics, and devices by various approaches including imaging and in-silico.

Clinical Research: AI enabled acceleration and facilitation of Phase I-IV clinical trials including patient stratification, enrollment, retention, adherence, and monitoring as well as project management approaches.

Medical Diagnostics and Devices: AI approaches that enable image, drug/device, or treatment enhancement; may include diagnostics, wearables and implantables.

Precision Medicine: AI-based approaches that enhance patient or population health solutions and care; includes patient data, and risk analytics, and genomics.

We also encourage and anticipate the participation of numerous large pharmaceutical, biotech, diagnostics, and medical devices firms investing in or utilizing AI in their operations as well as the full gamut of tech firms participating in healthcare.

What is the expectation that all member companies will adhere to the practices & guidelines developed by the AAIH?

As an industry convener, the AAIH will lead discussions on standardization and guidance. We embrace a multi-stakeholder approach; companies and institutions in particular healthcare applications are asked to participate in setting industry standards and crafting our guidelines which will inform ongoing conversations with regulatory bodies. Our view is that members committed to developing a sustainable and ethical industry will see participation in these drafted standards and guidelines as mutually beneficial, and will support universal compliance.

What are the key membership benefits for participation in AAIH?

Advocacy: Representation to healthcare and policymakers influencing the markets in which Healthcare AI will operate.

Community/ Networking: While this community by its very nature will be virtual and distributed, AAIH will offer an opportunity for leaders in the community to convene and discuss issues, challenges, and opportunities within the sector. We will create both a virtual and event-based networking service to facilitate business interactions, collaborations, and partnerships.

• For Technology Developers: Engagement with AAIH offers a unique opportunity to engage with key stakeholders in other verticals, as well as potential client bases such as large pharma or patient populations.

• For Users/Integrators: Participation in AAIH offers consumers and data analysts the chance to engage with developers, to have their voices heard, and requirements delivered at the executive level.

• For Investors: Participation in AAIH offers a view into key developments in the industry, and an opportunity to engage with the entrepreneurs making AI in Healthcare a reality.

Access to information: We expect AAIH to become a repository for information, data, and metrics to track sector performance and provide other relevant information to support successful commercial adoption of these technologies.

Access to experts for AI enabled/enhanced Biomedical discovery and care delivery: AAIH will provide a forum for members to effectively tap into AI Subject Matter Experts for input, and to view associated platforms for acceleration of internal R&D programs to increase the probability of success.

Accreditation and Standardization: AAIH will lead the effort to develop relevant standards to support broader use and adoption of AI in healthcare. In addition, AAIH will begin development of an accreditation process to certify companies/organizations claiming to provide AI services in healthcare.

Communications/PR: AAIH will be a voice for the sector and will manage interactions with the media, public, and other key stakeholder groups.

Education: Educational outreach will begin as an activity of AAIH, and as demand increases may shift towards an education-focused foundation for AI in Healthcare.